A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

作者：Hofmeister Craig C^*; Williams Nita; Geyer Susan; Hade Erinn M; Bowers Mindy A; Earl Christian T; Vaughn John; Bingman Anissa; Humphries Kristina; Lozanski Gerard; Baiocchi Robert A; Jaglowski Samantha M; Blum Kristie; Porcu Pierluigi; Flynn Joseph; Penza Sam; Benson Don M; Andritsos Leslie A; Devine Steven M

来源：Leukemia and Lymphoma, 2015, 56(4): 1043-1049.

DOI：10.3109/10428194.2014.963073

• Chemotherapeutic approaches
• lymphoma and Hodgkin disease
• vaccines

Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (>0.35 mu g/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy.

• 出版日期2015-4